Vibegron 50 mg Once Daily Improves OABSS, OAB-q SF Score in OAB Patients ≥80 Years Old in Real-World Clinical Settings and Switching from Other OAB Drugs May Reduce Residual Urine Volume
Takahira Kuno,1,2 Kenji Tamura,1,3 Nobutaka Shimizu,1 Hideo Fukuhara,1 Satoshi Fukata,1 Shingo Ashida,1 Takashi Karashima,1 Hirofumi Satake,3 Kohji Sawada,4 Ichiro Yamasaki,5 Fumito Komatsu,2 Hajime Kuroiwa,6 Motoaki Saito,7 Keiji Inoue1 1Department of Urology, Kochi Medical School, Kochi University...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-05-01
|
| Series: | Research and Reports in Urology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/vibegron-50-mg-once-daily-improves-oabss-oab-q-sf-score-in-oab-patient-peer-reviewed-fulltext-article-RRU |
| _version_ | 1797821673661005824 |
|---|---|
| author | Kuno T Tamura K Shimizu N Fukuhara H Fukata S Ashida S Karashima T Satake H Sawada K Yamasaki I Komatsu F Kuroiwa H Saito M Inoue K |
| author_facet | Kuno T Tamura K Shimizu N Fukuhara H Fukata S Ashida S Karashima T Satake H Sawada K Yamasaki I Komatsu F Kuroiwa H Saito M Inoue K |
| author_sort | Kuno T |
| collection | DOAJ |
| description | Takahira Kuno,1,2 Kenji Tamura,1,3 Nobutaka Shimizu,1 Hideo Fukuhara,1 Satoshi Fukata,1 Shingo Ashida,1 Takashi Karashima,1 Hirofumi Satake,3 Kohji Sawada,4 Ichiro Yamasaki,5 Fumito Komatsu,2 Hajime Kuroiwa,6 Motoaki Saito,7 Keiji Inoue1 1Department of Urology, Kochi Medical School, Kochi University, Nankoku, Japan; 2Department of Urology, Tosa Municipal Hospital, Tosa, Japan; 3Department of Urology, Chikamori Hospital, Kochi, Japan; 4Department of Urology, Kochi Prefectural Hata Kenmin Hospital, Sukumo, Japan; 5Department of Urology, Kubokawa Hospital, Takaoka-gun, Japan; 6Integrated Center for Advanced Medical Technologies (ICAM-Tech), Kochi Medical School, Nankoku, Japan; 7Department of Pharmacology, Kochi Medical School, Kochi University, Nankoku, JapanCorrespondence: Kenji Tamura, Email tamurak@kochi-u.ac.jpObjective: The treatment effects of vibegron have not previously been evaluated in a prospective, non-interventional observational study of elderly Japanese patients, particularly those ≥ 80 years old. In addition, no reports have referred to residual urine volume in switching cases. We therefore grouped patients by condition and investigated the treatment effects of vibegron on Overactive Bladder Symptom Score (OABSS), Overactive Bladder Questionnaire Short Form (OAB-q SF), and residual urine volume in each group.Methods: This multicenter, prospective, non-interventional, observational study consecutively enrolled OAB patients with total OABSS score ≥ 3 and OABSS question 3 score ≥ 2. Sixty-three patients from six centers were recruited. Vibegron 50 mg once daily was administered for 12 weeks as first-line monotherapy (first-line group), monotherapy switching from antimuscarinics or mirabegron due to failure of prior therapy (no washout period), or combination therapy with antimuscarinics (second-line group). OABSS, OAB-q SF, and residual urine volume were collected after 4 and 12 weeks. Adverse events were also recorded at each visit.Results: Of the 63 patients registered, 61 were eligible for analysis (first line, n=36; second line, n=25). The OABSS, excluding daytime frequency scores, and OAB-q SF scale showed significant improvement in all conditions. Switching from mirabegron to vibegron significantly reduced residual urine volume. No serious treatment-related adverse events were encountered.Conclusion: Vibegron 50 mg once daily significantly improved OABSS and OAB-q SF even in patients ≥ 80 years old. Notably, switching from mirabegron to vibegron resulted in significant improvements to residual urine volume.Keywords: selective β 3-adrenoreceptor agonist, overactive bladder, residual urine volume, vibegron, mirabegron |
| first_indexed | 2024-03-13T09:56:16Z |
| format | Article |
| id | doaj.art-0ad4fa351d9d4de7b285dfbb20ff297e |
| institution | Directory Open Access Journal |
| issn | 2253-2447 |
| language | English |
| last_indexed | 2024-03-13T09:56:16Z |
| publishDate | 2023-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Research and Reports in Urology |
| spelling | doaj.art-0ad4fa351d9d4de7b285dfbb20ff297e2023-05-23T18:52:22ZengDove Medical PressResearch and Reports in Urology2253-24472023-05-01Volume 1515716483907Vibegron 50 mg Once Daily Improves OABSS, OAB-q SF Score in OAB Patients ≥80 Years Old in Real-World Clinical Settings and Switching from Other OAB Drugs May Reduce Residual Urine VolumeKuno TTamura KShimizu NFukuhara HFukata SAshida SKarashima TSatake HSawada KYamasaki IKomatsu FKuroiwa HSaito MInoue KTakahira Kuno,1,2 Kenji Tamura,1,3 Nobutaka Shimizu,1 Hideo Fukuhara,1 Satoshi Fukata,1 Shingo Ashida,1 Takashi Karashima,1 Hirofumi Satake,3 Kohji Sawada,4 Ichiro Yamasaki,5 Fumito Komatsu,2 Hajime Kuroiwa,6 Motoaki Saito,7 Keiji Inoue1 1Department of Urology, Kochi Medical School, Kochi University, Nankoku, Japan; 2Department of Urology, Tosa Municipal Hospital, Tosa, Japan; 3Department of Urology, Chikamori Hospital, Kochi, Japan; 4Department of Urology, Kochi Prefectural Hata Kenmin Hospital, Sukumo, Japan; 5Department of Urology, Kubokawa Hospital, Takaoka-gun, Japan; 6Integrated Center for Advanced Medical Technologies (ICAM-Tech), Kochi Medical School, Nankoku, Japan; 7Department of Pharmacology, Kochi Medical School, Kochi University, Nankoku, JapanCorrespondence: Kenji Tamura, Email tamurak@kochi-u.ac.jpObjective: The treatment effects of vibegron have not previously been evaluated in a prospective, non-interventional observational study of elderly Japanese patients, particularly those ≥ 80 years old. In addition, no reports have referred to residual urine volume in switching cases. We therefore grouped patients by condition and investigated the treatment effects of vibegron on Overactive Bladder Symptom Score (OABSS), Overactive Bladder Questionnaire Short Form (OAB-q SF), and residual urine volume in each group.Methods: This multicenter, prospective, non-interventional, observational study consecutively enrolled OAB patients with total OABSS score ≥ 3 and OABSS question 3 score ≥ 2. Sixty-three patients from six centers were recruited. Vibegron 50 mg once daily was administered for 12 weeks as first-line monotherapy (first-line group), monotherapy switching from antimuscarinics or mirabegron due to failure of prior therapy (no washout period), or combination therapy with antimuscarinics (second-line group). OABSS, OAB-q SF, and residual urine volume were collected after 4 and 12 weeks. Adverse events were also recorded at each visit.Results: Of the 63 patients registered, 61 were eligible for analysis (first line, n=36; second line, n=25). The OABSS, excluding daytime frequency scores, and OAB-q SF scale showed significant improvement in all conditions. Switching from mirabegron to vibegron significantly reduced residual urine volume. No serious treatment-related adverse events were encountered.Conclusion: Vibegron 50 mg once daily significantly improved OABSS and OAB-q SF even in patients ≥ 80 years old. Notably, switching from mirabegron to vibegron resulted in significant improvements to residual urine volume.Keywords: selective β 3-adrenoreceptor agonist, overactive bladder, residual urine volume, vibegron, mirabegronhttps://www.dovepress.com/vibegron-50-mg-once-daily-improves-oabss-oab-q-sf-score-in-oab-patient-peer-reviewed-fulltext-article-RRUselective 3-adrenoreceptor agonistoveractive bladderresidual urine volumevibegronmirabegron |
| spellingShingle | Kuno T Tamura K Shimizu N Fukuhara H Fukata S Ashida S Karashima T Satake H Sawada K Yamasaki I Komatsu F Kuroiwa H Saito M Inoue K Vibegron 50 mg Once Daily Improves OABSS, OAB-q SF Score in OAB Patients ≥80 Years Old in Real-World Clinical Settings and Switching from Other OAB Drugs May Reduce Residual Urine Volume Research and Reports in Urology selective 3-adrenoreceptor agonist overactive bladder residual urine volume vibegron mirabegron |
| title | Vibegron 50 mg Once Daily Improves OABSS, OAB-q SF Score in OAB Patients ≥80 Years Old in Real-World Clinical Settings and Switching from Other OAB Drugs May Reduce Residual Urine Volume |
| title_full | Vibegron 50 mg Once Daily Improves OABSS, OAB-q SF Score in OAB Patients ≥80 Years Old in Real-World Clinical Settings and Switching from Other OAB Drugs May Reduce Residual Urine Volume |
| title_fullStr | Vibegron 50 mg Once Daily Improves OABSS, OAB-q SF Score in OAB Patients ≥80 Years Old in Real-World Clinical Settings and Switching from Other OAB Drugs May Reduce Residual Urine Volume |
| title_full_unstemmed | Vibegron 50 mg Once Daily Improves OABSS, OAB-q SF Score in OAB Patients ≥80 Years Old in Real-World Clinical Settings and Switching from Other OAB Drugs May Reduce Residual Urine Volume |
| title_short | Vibegron 50 mg Once Daily Improves OABSS, OAB-q SF Score in OAB Patients ≥80 Years Old in Real-World Clinical Settings and Switching from Other OAB Drugs May Reduce Residual Urine Volume |
| title_sort | vibegron 50 mg once daily improves oabss oab q sf score in oab patients ge 80 years old in real world clinical settings and switching from other oab drugs may reduce residual urine volume |
| topic | selective 3-adrenoreceptor agonist overactive bladder residual urine volume vibegron mirabegron |
| url | https://www.dovepress.com/vibegron-50-mg-once-daily-improves-oabss-oab-q-sf-score-in-oab-patient-peer-reviewed-fulltext-article-RRU |
| work_keys_str_mv | AT kunot vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume AT tamurak vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume AT shimizun vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume AT fukuharah vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume AT fukatas vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume AT ashidas vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume AT karashimat vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume AT satakeh vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume AT sawadak vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume AT yamasakii vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume AT komatsuf vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume AT kuroiwah vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume AT saitom vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume AT inouek vibegron50mgoncedailyimprovesoabssoabqsfscoreinoabpatientsge80yearsoldinrealworldclinicalsettingsandswitchingfromotheroabdrugsmayreduceresidualurinevolume |